13th May 2009

Company Announcements Office
Australian Securities Exchange

- **Nanosonics instructs agent to submit 510(k) application to the US FDA**
- **Trophon Tender Successes**

U.S. FDA Submission

Nanosonics Limited (ASX: NAN) has today instructed its US based consultant, Safis Solutions, to submit its 510(k) application to the Food and Drug Administration (FDA) in the United States for the Trophon® EPR and NanoNebulant® consumable.

In order to meet the stringent requirements of the FDA, the submission required further extensive microbiological testing of the Trophon device. The Company has appointed Safis Solutions as its US based consultant to coordinate contact with the FDA during the application process, with the FDA targeting an initial review and feedback within 90 days from lodgement. Prospective distribution partners estimate the size of the US market for the Trophon device to be in excess of AU$200 million. The Company is in advanced discussions with potential distributors for the US and Canada.

As previously announced, Nanosonics has received regulatory approval for the Trophon EPR and consumable in Europe, achieving CE Mark in April 2008, Australian approval from the Therapeutic Goods Administration and, in New Zealand, approval from the New Zealand Medicines and Medical Devices Safety Authority.

The Company remains on track for the controlled roll-out of the Trophon EPR and consumables into Europe in Q4-FY2009, with initial sales into France, Germany and the UK.

Tender Successes

Nanosonics has begun its Australian sales program with successful tenders for installations in public hospitals and private clinics, where the product has been favourably received. Support for the marketing program has recently been assisted by the Trophon EPR being specified in two Australian state government tenders for the provision of disinfection technology. These tenders include a large public hospital in Victoria, where the Trophon EPR was named as a condition of tender for the supply of a variety of ultrasound equipment

from third parties. In Western Australia, another major public hospital recently awarded a tender where the Trophon EPR was identified as the favoured method of high level disinfection for ultrasound probes.

Feedback from end users has confirmed the ease of use of the Trophon with no risk of exposure to toxic chemicals by staff or patients.

Product Pipeline

Nanosonics' primary focus is on driving the commercialisation of the Trophon EPR in international markets, in parallel with the application of its research and development capabilities into a product pipeline of commercial opportunities. The Company has developed pre-commercial prototypes of additional devices and is in discussions with potential partners to fast track market entry.

David Radford
Chief Executive

For more information please contact David Radford or Chris Grundy, Chief Financial Officer, at +61-2-8063 1600.

About Nanosonics

Nanosonics Limited is developing a portfolio of decontamination products designed to reduce the spread of infection. The Company owns intellectual property relating to a unique disinfection and sterilisation technology which can be suited to a variety of markets.

Initial market applications are designed for the reprocessing of reusable medical instruments. The Company's first product is designed to disinfect Ultrasound Transducers. In parallel with the commercialisation of this product, Nanosonics is also developing other medical applications and exploring opportunities for its proprietary technology in other industries.

For more information about Nanosonics please visit www.nanosonics.com.au